Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Hypertension. 2013 Mar;61(3):673–680. doi: 10.1161/HYPERTENSIONAHA.111.00241

Figure 8.

Figure 8

Intrarenal interstitial fenoldopam-induced natriruesis is abolished by intrarenal D1-LIKE receptor antagonist SCH-23390 (SCH) or AT2R antagonist PD-123319 (PD) in anesthetized, uninephrectomized Sprague-Dawley rats. Vehicle infusion, white bars; fenoldopam (1 μg/kg/min) infusion, black bars; fenoldopam + PD infusion, gray bars; fenoldopamn + SCH infusion, striped bars. Data are expressed as mean ± 1 SE. Numbers on the abscissa refer to experimental one-hour periods. * P<0.01, ** P<0.001 from vehicle control. Adapted from Salomone LJ et al. Hypertension. 2007;49:155–161 and Padia SH et al. Hypertension. 2012;59:437–445.